AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings
New York, Jan 25, 2026, 10:56 EST — Market closed AbbVie shares ticked up 0.5% to $219.26 on Friday, despite news from India that its patent application for the blood-cancer drug venetoclax was rejected by the country’s patent office. (The Economic Times) The India decision carries less weight for Monday’s open than the larger issue it raises: how fast competitors…